MZMaría Paula Zafra-Sierra

María Paula Zafra-Sierra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


María Paula Zafra-Sierra has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Predictors of Multiple Sclerosis After Clinically Isolated Syndrome: A Systematic Review and Meta‐Analysis

    by María Paula Zafra‐Sierra, Carolina Ferreira‐Atuesta, Daniela Sofía Rodríguez, Jairo Gaitán, Susana Otero, Mar Tintoré, Fred Lublin, Gavin Giovannoni, Jaime Toro, Saúl Reyes

    Background: Most people with multiple sclerosis (MS) present with a clinically isolated syndrome (CIS); however, not all individuals with CIS are subsequently diagnosed with MS. Methods: A systematic literature review was conducted until December 2025. Observational studies of adults with CIS that were later diagnosed with MS were included. Odds ratios (ORs) were pooled using random‐effects meta‐analysis. Heterogeneity was assessed with I 2 , sensitivity analyses with leave‐one‐out procedures, and publication bias with funnel plots and Egger's test. Meta‐regression was performed to explore further sources of heterogeneity when appropriate. Results: Seventy‐two studies with 9915 adults were included. In the meta‐analysis, younger age (OR = 1.6, p < 0.01) and multifocal presentation (OR = 1.55, p = 0.02) were associated with a diagnosis of MS after a CIS. Magnetic resonance imaging findings, including a higher number of T2 lesions (OR = 7.46, p = 0.02), periventricular lesions (OR = 4.08, p < 0.01), corpus callosum lesions (OR = 14.89, p = 0.02), infratentorial lesions (OR = 2.16, p = 0.03), spinal cord lesions (OR = 1.4, p = 0.03), and gadolinium‐enhancing lesions (OR = 1.91, p = 0.01), as well as cerebrospinal fluid inflammatory markers such as oligoclonal bands (OR = 3.57, p < 0.01) and pleocytosis (OR = 3.34, p = 0.02), were also associated with a subsequent diagnosis of MS. Conclusions: This meta‐analysis identified factors associated with an increased likelihood of MS after a CIS. These findings may help identify high‐risk individuals and guide personalized treatment strategies.

  • Open Access

    Controversias en neuroinmunología: esclerosis múltiple y otras enfermedades desmielinizantes

    by Ana C. Villegas, David CuélLar-Giraldo, Estefanía Rojo-Bustamante, María Paula Zafra-Sierra, Lisseth Burbano, Thomas Medina, Laura Andrea Serna-Corredor, María Camila Ramírez, Daniela Sofía Rodríguez, Marcela Urbano, et al.

    La esclerosis múltiple es la enfermedad desmielinizante más frecuente del sistema nervioso. En las últimas dos décadas, se han logrado importantes avances, como la identificación de vías inmunológicas clave, nuevos biomarcadores y el desarrollo de inmunoterapias efectivas. Sin embargo, aún persisten áreas de incertidumbre y desafíos. A nivel mundial, se ha observado un incremento notorio de los casos de esclerosis múltiple. En Colombia, por ejemplo, los estudios más recientes han reportado un cambio de la prevalencia menor de 5 por cada 100 000 habitantes a 7,5 casos por cada 100 000 habitantes. Es esencial que los neurólogos estén al tanto de los tratamientos actuales para brindar asesoramiento adecuado a estos pacientes.Esta revisión aborda ocho controversias relevantes en esclerosis múltiple y otras enfermedades desmielinizantes, basada en la evidencia más reciente. Los temas incluyen la suspensión de tratamientos en adultos mayores, el uso de pruebas genéticas para el diagnóstico, las recomendaciones sobre planificación familiar, la prevención de recaídas posparto y el espectro de neuromielitis óptica. También se analizan la indicación de terapia con células madre, el riesgo de neoplasias malignas asociadas a la inmunoterapia, el manejo de la linfopenia y las estrategias para mitigar el efecto de rebote al suspender los tratamientos modificadores de la enfermedad. Cada controversia incluye recomendaciones para orientar la toma de decisiones en la práctica clínica diaria, adaptándose a las realidades de países como Colombia, donde son cruciales los avances en formación neurológica y acceso a tratamientos.

  • Open Access

    Association of the timing and type of acute symptomatic seizures with post-stroke epilepsy and mortality

    by Kai Michael Schubert, Dominik Zieglgänsberger, Giulio Bicciato, Laura Abraira, Estevo Santamarina, José Álvarez-Sabín, Carolina Ferreira-Atuesta, Mira Katan, Lucia Sinka, Robert Terziev, et al.

    Background Acute symptomatic seizures (ASyS) increase the risk of epilepsy and mortality after a stroke. The impact of the timing and type of ASyS remains unclear. Methods This multicenter cohort study included data from nine centers between 2002 and 2018, with final analysis in February 2024. The study included 4,552 adults (2,005 female; median age 73 years) with ischemic stroke and no seizure history. We examined ASyS occurring within seven days after stroke. Main outcomes were all-cause mortality and epilepsy. Validation in three separate cohorts included 74 adults with ASyS. Results The ten-year risk of post-stroke epilepsy ranged from 41% to 94%, and mortality from 36% to 100%, depending on ASyS type and timing. ASyS on stroke onset day had a higher epilepsy risk (aHR 2.3, 95% CI 1.3-4.0, p=0.003) compared to later ASyS. Status epilepticus had the highest epilepsy risk (aHR 9.6, 95% CI 3.5-26.7, pConclusions ASyS timing and type significantly affect epilepsy and mortality risk after stroke, improving epilepsy prediction and guiding patient counseling.


  • Time of Stroke Onset in Coronavirus Disease 2019 Patients Around the Globe: A Systematic Review and Analysis

    by Natalia Valencia-Enciso, Mónica Ortiz-Pereira, María Paula Zafra-Sierra, Laura Espinel-Gómez, Hernan Bayona